Targets › SLC6A9
2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 3; Psychiatry, Metabolic and endocrine; next expected readout Apr 2028.
Sodium- and chloride-dependent glycine transporter. Essential for regulating glycine concentrations at inhibitory glycinergic synapses..; FUNCTION: [Isoform GlyT-1B]: Sodium- and chloride-dependent glycine transporter..; FUNCTION: [Isoform GlyT-1C]: Sodium- and chloride-dependent glycine transporter. (UniProt, P48067)
Open in Phaseline: the race on SLC6A9, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Disc Medicine | Bitopertin (DISC-1459) Glycine transporter 1 inhibitor | SLC6A9 | Phase 3 | Erythropoietic Protoporphyria (EPP) | – |
| National Cheng-Kung University Hospital | Sodium Benzoate Glycine transporter 1 (GlyT1) inhibitor; increases synaptic glycine to enhance NMDA recept | SLC6A9 | Phase 2 | Symptom, Cognitive | Apr 2028 |
Symptom, Cognitive (1) Erythropoietic Protoporphyria (EPP) (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.